Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,230,329 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive scheme.
Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies. Please see http://www.anataralifesciences.com for further background.
At the Australasian Pig Science Association Conference in Melbourne this week, Dr Trish Holyoake & Dr Tracey Mynott presented a poster highlighting the comparable efficacy of a single dose of Anatara's (ASX:ANR) Detach(R) product to in-feed Zinc oxide in reducing diarrhoea and antibiotic treatments in post-weaning piglets.
Anatara Lifesciences Ltd (ASX:ANR) provides the Chairman's address to shareholders.
Anatara Lifesciences Ltd (ASX:ANR) Dr Tracey Mynott Presents at TRI Science Business Inspiration Series
Anatara Lifesciences (ASX:ANR) CSO, Dr Tracey Mynott, was recently invited to present at the Translational Research Institute's Science Business Inspiration Series. The series was launched with Session 1 "The whole journey: from idea to reality".
Anatara Lifesciences (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors this week by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.
Anatara Lifesciences Ltd (ASX:ANR) provides the Company's Annual Report 2017 Update.
Anatara Lifesciences Limited (ASX:ANR) has today undertaken to extend by 12 months the expiry date of 250,000 Options which Anatara issued to the Pork Cooperative Research Centre in 2015.
Anatara Lifesciences Ltd (ASX:ANR) and Zoetis to Negotiate Terms of International Detach(R) Commercial Agreement
Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that global animal health company, Zoetis Inc. has exercised its option to negotiate a commercial agreement for the worldwide development, distribution and marketing of Detach(R), with terms to be agreed.
FINANCE VIDEO: Anatara Lifesciences Ltd (ASX:ANR) Gold Coast Investment Showcase Investor Presentation
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation for the Gold Coast Investment Showcase (June 21st & 22nd 2017).
Wilsons maintain a BUY rating and $1.66 price target. Anatara's recent stock underperformance has simply reflected a slow quarter for news in the lead-up to a significant inflection point in the 2H.